Happy to have participated in #SERENA6, using ctDNA to tailor an early switch strategy for metastatic HR+ disease. Could make ctDNA actually ACTIONable in breast for the first time! astrazeneca.com/media-centre/p…

A great opportunity! Join if you can. Sandra Levine Young Women's Breast Cancer Program Atrium Health

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

Most viewed in the last 7 days from JAMA Oncology: Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy. ja.ma/4hlrF9m

Ivermectin does nothing in breast cancer this trial of Ivermectin + Immunotherapy has an overall response rate of 12.5%, which is the same as single agent immunotherapy. Don’t misinterpret this being presented as it actually doing something. It’s a negative trial. #bcsm

MINI Trial by Dr Sohn shows 30 month PFS is 1st Line ER+, HER2+ MBC with chemotherapy free regimen of tras, letrozole and ribociclib. Further evidence post-PATINA that optimal targeting of estrogen receptor with CDK4/6 in HER2+, HR+ disease has excellent efficacy. #bcsm

A first-line metastatic TNBC progression free survival beyond 1 year is very welcome for our patients and this was mostly PDL-1 negative. #bcsm #ASCO25

VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. Erika Hamilton, MD OncoAlert #ASCO25

Great inavo OS data. The 2 year delay of chemo is impressive. But questioning the small subgroup of >65 and worsening OS. Small number of patients highlighting the fact that we can’t bias our trial by not accruing eligible patients based on our bias. #ASCO25 #bcsm

Data for the oral taxane, DHP107, were pretty compelling. Looks the 'same' as IV paclitaxel; met all non-inferiority criteria, and K-M curves pass the eyeball test. It would be terrific to have an oral paclitaxel option for patients.

DHP107 is non inferior to paclitaxel in this 🇰🇷 study presented by Sung-Bae Kim #ASCO25

Congratulations Heidi Klepin on the ASCO Award for Geriatric Oncology! Master clinician, educator, scientist and just overall good human 🩷 Wake Forest Baptist - Comprehensive Cancer Center Atrium Health Wake Forest Baptist

And there you have it folks the standard of care has been changed #ASCO25 #TNBC #MBC

#ASCENT04 showing sacituzumab + pembro better for 1L PDL1+ TNBC than chemo + pembro PFS: 7.8 vs. 11.2 mo, HR 0.65 ORR higher and more durable w/ SG Fewer discontinuations and reductions w/ SG #ASCO25 #bcsm 🎶 "movin' on up" 🎶 Sara Tolaney

First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️ Crossover 80% Sacituzumab Offered! Very few patients with prior IO, few who relapsed within 6-12 months. OS looks similar but early days. #bcsm great job Sara Tolaney !!

🎉 Congratulations to Dr. Heidi Klepin for receiving the prestigious B.J. Kennedy Geriatric Oncology Award at #ASCO25! It highlights her commitment & leadership in improving care for older adults with cancer through clinical research & practice. Atrium Health Wake Forest Baptist Wake Forest University School of Medicine

3rd NEJM publication for #bcsm at #ASCO25 in the last 2 days (that I'm aware of!). #camizestrant #ESR1 Come to plenary Hall B1 today at 1pm to hear the presentation by Dr. Turner and discussion about potential impact by Angie DeMichele, MD, MSCE, FASCO! nejm.org/doi/full/10.10…

As anticipated, SERENA-6 creates a lot of questions. PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing. #ASCO25

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

We present the #FiveUnder5 🕘, your go-to roundup of the top 5️⃣ #oncology videos of the week. View the clips 📹: hubs.li/Q03vZt400 Icahn School of Medicine at Mount Sinai Cleveland Clinic Eileen M O’Reilly Memorial Sloan Kettering Cancer Center Katherine Ansley, MD Wake Forest University School of Medicine Benjamin Weinberg, MD, FACP Georgetown Lombardi